Glioblastoma therapy options evolve past temozolomide and TTFields
Tumour-treating fields maturity, IDH-mutant glioma vorasidenib approval, and emerging mechanism-targeted programs are reshaping glioma management.
Glioblastoma has been a temozolomide-and-radiation category with tumour-treating fields as the major addition. Vorasidenib (IDH inhibitor) is now approved for IDH-mutant grade 2 glioma, marking the first targeted therapy in adult diffuse glioma. Late-stage programs in glioblastoma (immunotherapy combinations, targeted therapy in molecularly-defined subgroups, novel delivery approaches across the blood-brain barrier) are reading out. The category is structurally evolving for the first time in over a decade.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.